RNTX RNTX Preclinical Study Costs — Research And Development Expense

Other product segments

Similar metrics at other companies

MPLTPreclinical Program — Research And Development Expense

$5.52M-9.2%

LBR

LBRXPreclinical — Direct Research And Development Expenses

$32.25K-93.0%

LON

LONAPreclinical Programs And Other Costs — Research And Development Expense Excluding Stockbased Or Depreciation Expense

$355K-11.9%

LBR

LBRXPreclinical And Other Direct Expenses — Direct Research And Development Expenses

$501K—

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

SRRKEarly Research — Research And Development Expense

$1.21M-16.8%

Questions, answered.

What is RNTX's preclinical study costs — research and development expense?

RNTX (RNTX) reported preclinical study costs — research and development expense of $0 in Q1 2026.

How has RNTX's preclinical study costs — research and development expense changed year-over-year?

RNTX's preclinical study costs — research and development expense decreased by 100.0% year-over-year, from $556K to $0.

What does preclinical study costs — research and development expense mean?

This metric represents the aggregate research and development expenditures specifically allocated to the preclinical stage of drug development for a particular product candidate or therapeutic program. It encompasses costs associated with laboratory testing, animal studies, and initial safety assessments required before human clinical trials can commence. Tracking these costs provides insight into the capital intensity and progress of early-stage pipeline assets.